The benefits of antioxidants or DHA/EPA supplementation for CF , although observed in some studies , are not consistent enough to recommend routine use of these supplements .
Antioxidant micronutrients and essential fatty acids supplementation intake appears to have a protective effect in some diseases such as cardiovascular disease , cancer , and asthma .
The aim of this study was to perform a systematic review to evaluate the effects of these nutrients on nutritional and clinical outcomes of patients with cystic fibrosis ( CF ) .
This is a systematic review of r and omized clinical trials ( RCTs ) in CF .
Effects of an Antioxidant‐enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial
Rationale : Cystic fibrosis ( CF ) is characterized by dietary antioxidant deficiencies , which may contribute to an oxidant‐antioxidant imbalance and oxidative stress . Objectives : Evaluate the effects of an oral antioxidant‐enriched multivitamin supplement on antioxidant concentrations , markers of inflammation and oxidative stress , and clinical outcomes . Methods : In this investigator‐initiated , multicenter , r and omized , double‐blind , controlled trial , 73 pancreatic‐insufficient subjects with CF 10 years of age and older with an FEV1 between 40 % and 100 % predicted were r and omized to 16 weeks of an antioxidant‐enriched multivitamin or control multivitamin without antioxidant enrichment . Endpoints included systemic antioxidant concentrations , markers of inflammation and oxidative stress , clinical outcomes ( pulmonary exacerbations , anthropometric measures , pulmonary function ) , safety , and tolerability . Measurements and Main Results : Change in sputum myeloperoxidase concentration over 16 weeks , the primary efficacy endpoint , was not significantly different between the treated and control groups . Systemic antioxidant ( & bgr;‐carotene , coenzyme Q10 , & ggr;‐tocopherol , and lutein ) concentrations significantly increased in the antioxidant‐treated group ( P < 0.001 for each ) , whereas circulating calprotectin and myeloperoxidase decreased in the treated group compared with the control group at Week 4 . The treated group had a lower risk of first pulmonary exacerbation requiring antibiotics than the control group ( adjusted hazard ratio , 0.50 ; P = 0.04 ) . Lung function and growth endpoints did not differ between groups . Adverse events and tolerability were similar between groups . Conclusions : Antioxidant supplementation was safe and well tolerated , result ing in increased systemic antioxidant concentrations and modest reductions in systemic inflammation after 4 weeks . Antioxidant treatment was also associated with a lower risk of first pulmonary exacerbation . Clinical trial registered with www . clinical trials.gov ( NCT01859390 )
The benefits of antioxidants or DHA/EPA supplementation for CF , although observed in some studies , are not consistent enough to recommend routine use of these supplements .
Antioxidant micronutrients and essential fatty acids supplementation intake appears to have a protective effect in some diseases such as cardiovascular disease , cancer , and asthma .
The aim of this study was to perform a systematic review to evaluate the effects of these nutrients on nutritional and clinical outcomes of patients with cystic fibrosis ( CF ) .
This is a systematic review of r and omized clinical trials ( RCTs ) in CF .